Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity
9/11 04:46
(RTTNews) - Eli Lilly and Co. (LLY) said that the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for Chronic Weight Management, a new option for the treatment of Obesity or Overweight with weight-related medical problems....